I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wr ...

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501 ____________________________ ...

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update CAMBRIDGE, MA, March 16, 2026 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Black Diamond Therapeutics is a cli ...

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCompany is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR altered GBM in Q2 2026 Cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, expected to be sufficient to fund operations into 2H of 2028 CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Blac ...

Summary of Black Diamond Therapeutics FY Conference Call Company Overview - **Company**: Black Diamond Therapeutics (NasdaqGS: BDTX) - **Industry**: Biotechnology, specifically focused on oncology - **Lead Product**: Silevertinib, a fourth-generation EGFR inhibitor Key Points and Arguments Product Development - Black Diamond is developing precision small molecule therapies, with silevertinib being the lead program currently in phase 2 development for non-small cell lung cancer (NSCLC) and glioblastoma (GBM) [2][8] - Silevertinib targets the epidermal growth factor receptor (EGFR) and is designed to inhibit non-classical mutations, which are prevalent in a significant portion of lung cancer patients [2][4] Market Opportunity - The market for EGFR inhibitors is substantial, with Tagrisso (osimertinib) expected to generate $8 billion in revenue this year [3] - Approximately 25% of EGFR mutant NSCLC patients have non-classical mutations, for which there are currently no effective treatments [4] - Silevertinib has shown a confirmed objective response rate of 60% and a disease control rate of 93% in clinical trials [6] Clinical Data - In a phase 2 trial, 43 patients were enrolled, with 35 distinct mutations identified, and over one-third had untreated brain metastases [5] - Silevertinib demonstrated an 86% CNS response rate, which is critical for patients with CNS metastases [6][15] - Adverse events (AEs) were manageable, with less than 10% of patients discontinuing due to AEs [7][18] Future Trials and Expectations - A phase 2 trial for GBM is set to initiate next quarter, with preliminary PFS data expected in the first half of 2028 [10][39] - The trial design includes a safety run-in phase to determine the optimal dosing of silevertinib in combination with standard care [10][34] Competitive Landscape - Comparisons were made with Furmonertinib, another EGFR inhibitor, highlighting differences in patient enrollment, mutational coverage, and CNS response rates [14][15] - The competitive landscape in oncology is noted to be dynamic, with the potential for market perceptions to shift as more data becomes available [62] Strategic Considerations - The company is exploring potential partnerships to enhance capital resources for pivotal studies, particularly in the frontline lung cancer population [24][25] - There is a focus on preserving shareholder value in any partnership agreements [24] Additional Important Information - The company has two other assets in its pipeline: BDTX-4933 (a Ras/Raf inhibitor) and BDTX-4876 (a preclinical FGFR inhibitor) [11] - The management expressed confidence in the enrollment rate for the GBM trial due to the high unmet need and enthusiasm from investigators [39] - The market's current valuation of the company may not fully reflect the potential of its pipeline and upcoming data releases [60][62]

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks. TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company’s revision of several models and price estimates throughout its biotechnology coverage, as well as an update to its 2026 Catalyst Tracker. Separately, on December 3, 2025, Black Dia ...

Company Overview - Black Diamond (BDTX) is part of the Medical sector, which includes 932 companies and ranks 8 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for BDTX's full-year earnings has increased by 39.2%, reflecting improved analyst sentiment [4] - Year-to-date, Black Diamond has returned 9.1%, outperforming the Medical sector's average return of 8.3% [4] Industry Context - Black Diamond operates within the Medical - Biomedical and Genetics industry, which consists of 453 stocks and ranks 88 in the Zacks Industry Rank [6] - The average return for stocks in this industry is 21.9% this year, indicating that BDTX is slightly underperforming compared to its industry peers [6] Comparative Analysis - Bionano Genomics, Inc. (BNGO) is another Medical stock that has shown strong performance, with a year-to-date return of 9.2% and a consensus EPS estimate increase of 46.2% over the past three months [5] - Both Black Diamond and Bionano Genomics are noteworthy for investors interested in the Medical sector due to their solid performance [7]

Core Viewpoint - Black Diamond (BDTX) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, making it a valuable tool for investors [2][4]. - The recent upgrade for Black Diamond reflects an improvement in the company's underlying business, likely leading to increased stock prices due to investor confidence [5]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Black Diamond is expected to earn $0.48 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 34.5% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Black Diamond's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Summary of Black Diamond Therapeutics FY Conference Call Company Overview - **Company**: Black Diamond Therapeutics (NasdaqGS: BDTX) - **Industry**: Precision oncology, specifically focusing on EGFR tyrosine kinase inhibitors - **Lead Asset**: BDTX-1535, a fourth-generation EGFR TKI targeting both classical and non-classical mutations in lung cancer and glioblastoma [4][6][26] Key Highlights BDTX-1535 Development - **Phase 2 Trial**: Initial data from a phase 2 trial in frontline lung cancer patients was released, showing a response rate benchmark of 60% was met [12][14] - **Patient Population**: The trial included 43 patients with 35 different non-classical mutations, with over a third presenting with untreated brain metastases [12][14] - **CNS Activity**: BDTX-1535 demonstrated an 86% CNS response rate among patients with measurable brain lesions, significantly higher than competitor Furmonertinib's 43% [14] Mechanism of Action - **Targeting Non-Classical Mutations**: BDTX-1535 is designed to address a broad spectrum of non-classical EGFR mutations, which are not effectively treated by existing therapies like Osimertinib [6][10] - **Brain Penetration**: The drug is engineered to penetrate the blood-brain barrier, which is critical for treating CNS metastases in lung cancer patients [6][28] Future Expectations - **Upcoming Data**: Progression-free survival (PFS) data is expected in the second quarter of 2026, which will be crucial for discussions with the FDA regarding pivotal trials [22][40] - **Partnerships**: The company is seeking a global partner, particularly one with a presence in Asia, to support the execution of a large phase 3 study while preserving shareholder value [24][25] Glioblastoma Research - **Phase 2 Trial Initiation**: BDTX-1535 will advance into a phase 2 trial for newly diagnosed glioblastoma patients, addressing the lack of effective EGFR inhibitors in this area [27][35] - **Unique Attributes**: The drug shows potent preclinical activity against EGFR variant 3, which is prevalent in glioblastoma, and has demonstrated high brain penetration [28][30] Financial and Strategic Outlook - **Cash Runway**: The company has a financial runway until the second half of 2028, supported by a $70 million upfront payment from a partnership with Servier for a RAF inhibitor [39][40] - **Market Opportunity**: The potential market for BDTX-1535 in non-small cell lung cancer is estimated at $2 billion, with significant opportunities in the recurrent setting and glioblastoma [26][27] Conclusion - Black Diamond Therapeutics is positioned to make significant advancements in the treatment of lung cancer and glioblastoma with BDTX-1535, focusing on addressing unmet medical needs through innovative drug design and strategic partnerships [4][24][40]